IER-START nomogram for prediction of three-month unfavorable outcome after thrombectomy for stroke.


Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 26 3 2019
medline: 26 10 2021
entrez: 26 3 2019
Statut: ppublish

Résumé

The applicability of the current models for predicting functional outcome after thrombectomy in strokes with large vessel occlusion (LVO) is affected by a moderate predictive performance. We aimed to develop and validate a nomogram with pre- and post-treatment factors for prediction of the probability of unfavorable outcome in patients with anterior and posterior LVO who received bridging therapy or direct thrombectomy <6 h of stroke onset. We conducted a cohort study on patients data collected prospectively in the Italian Endovascular Registry (IER). Unfavorable outcome was defined as three-month modified Rankin Scale (mRS) score 3-6. Six predictors, including NIH Stroke Scale (NIHSS) score, age, pre-stroke mRS score, bridging therapy or direct thrombectomy, grade of recanalization according to the thrombolysis in cerebral ischemia (TICI) grading system, and onset-to-end procedure time were identified a priori by three stroke experts. To generate the IER-START, the pre-established predictors were entered into a logistic regression model. The discriminative performance of the model was assessed by using the area under the receiver operating characteristic curve (AUC-ROC). A total of 1802 patients with complete data for generating the IER-START was randomly dichotomized into training ( The IER-START nomogram is the first prognostic model developed and validated in the largest population of stroke patients currently candidates to thrombectomy which reliably calculates the probability of three-month unfavorable outcome.

Sections du résumé

BACKGROUND
The applicability of the current models for predicting functional outcome after thrombectomy in strokes with large vessel occlusion (LVO) is affected by a moderate predictive performance.
AIMS
We aimed to develop and validate a nomogram with pre- and post-treatment factors for prediction of the probability of unfavorable outcome in patients with anterior and posterior LVO who received bridging therapy or direct thrombectomy <6 h of stroke onset.
METHODS
We conducted a cohort study on patients data collected prospectively in the Italian Endovascular Registry (IER). Unfavorable outcome was defined as three-month modified Rankin Scale (mRS) score 3-6. Six predictors, including NIH Stroke Scale (NIHSS) score, age, pre-stroke mRS score, bridging therapy or direct thrombectomy, grade of recanalization according to the thrombolysis in cerebral ischemia (TICI) grading system, and onset-to-end procedure time were identified a priori by three stroke experts. To generate the IER-START, the pre-established predictors were entered into a logistic regression model. The discriminative performance of the model was assessed by using the area under the receiver operating characteristic curve (AUC-ROC).
RESULTS
A total of 1802 patients with complete data for generating the IER-START was randomly dichotomized into training (
CONCLUSIONS
The IER-START nomogram is the first prognostic model developed and validated in the largest population of stroke patients currently candidates to thrombectomy which reliably calculates the probability of three-month unfavorable outcome.

Identifiants

pubmed: 30907302
doi: 10.1177/1747493019837756
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

412-420

Commentaires et corrections

Type : ErratumIn

Auteurs

Manuel Cappellari (M)

Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Salvatore Mangiafico (S)

Ospedale Careggi-University Hospital, Firenze, Italy.

Valentina Saia (V)

Santa Corona Hospital, Pietra Ligure, Italy.

Giovanni Pracucci (G)

University of Florence, Firenze, Italy.

Sergio Nappini (S)

Ospedale Careggi-University Hospital, Firenze, Italy.

Patrizia Nencini (P)

University of Florence, Firenze, Italy.

Daniel Konda (D)

Policlinico Tor Vergata, Roma, Italy.

Fabrizio Sallustio (F)

Policlinico Tor Vergata, Roma, Italy.

Stefano Vallone (S)

Ospedale Civile S. Agostino-Estense - University Hospital, Modena, Italy.

Andrea Zini (A)

IRCCS Istituto delle Scienze Neurologiche, Maggiore Hospital, Bologna, Italy.

Sandra Bracco (S)

Ospedale S. Maria delle Scotte-University Hospital, Siena, Italy.

Rossana Tassi (R)

Ospedale S. Maria delle Scotte-University Hospital, Siena, Italy.

Mauro Bergui (M)

Città della Salute e della Scienza-Molinette, Torino, Italy.

Paolo Cerrato (P)

Città della Salute e della Scienza-Molinette, Torino, Italy.

Antonio Pitrone (A)

Policlinico G. Martino, Messina, Italy.

Francesco Grillo (F)

Policlinico G. Martino, Messina, Italy.

Andrea Saletti (A)

Arcispedale S. Anna-University Hospital, Ferrara, Italy.

Alessandro De Vito (A)

Arcispedale S. Anna-University Hospital, Ferrara, Italy.

Roberto Gasparotti (R)

Spedali Civili, Brescia, Italy.

Mauro Magoni (M)

Spedali Civili, Brescia, Italy.

Edoardo Puglielli (E)

Ospedale Civile Mazzini, Teramo, Italy.

Alfonsina Casalena (A)

Ospedale Civile Mazzini, Teramo, Italy.

Francesco Causin (F)

Azienda Ospedaliero-Univeristaria, Padova, Italy.

Claudio Baracchini (C)

Azienda Ospedaliero-Univeristaria, Padova, Italy.

Lucio Castellan (L)

IRCCS San Martino-IST, Genova, Italy.

Laura Malfatto (L)

IRCCS San Martino-IST, Genova, Italy.

Roberto Menozzi (R)

Ospedale Universitario, Parma, Italy.

Umberto Scoditti (U)

Ospedale Universitario, Parma, Italy.

Chiara Comelli (C)

Ospedale San Giovanni Bosco, Torino, Italy.

Enrica Duc (E)

Ospedale San Giovanni Bosco, Torino, Italy.

Alessio Comai (A)

Ospedale Centrale, Bolzano, Italy.

Enrica Franchini (E)

Ospedale Centrale, Bolzano, Italy.

Mirco Cosottini (M)

Ospedale Cisanello, Pisa, Italy.

Michelangelo Mancuso (M)

Ospedale Cisanello, Pisa, Italy.

Simone Peschillo (S)

Sapienza University Hospital, Roma, Italy.

Manuela De Michele (M)

Sapienza University Hospital, Roma, Italy.

Andrea Giorgianni (A)

Ospedale Universitario Circolo, ASST Sette Laghi, Varese, Italy.

Maria Luisa Delodovici (M)

Ospedale Universitario Circolo, ASST Sette Laghi, Varese, Italy.

Elvis Lafe (E)

San Matteo Hospital & C. Mondino Foundation, Pavia, Italy.

Maria F Denaro (MF)

Stroke Unit, IRCCS Mondino Foundation, Pavia, Italy.

Nicola Burdi (N)

Ospedale SS. Annunziata, Taranto, Italy.

Saverio Internò (S)

Ospedale SS. Annunziata, Taranto, Italy.

Nicola Cavasin (N)

Ospedale dell'Angelo, USSL3 Serenissima, Mestre, Italy.

Adriana Critelli (A)

Ospedale dell'Angelo, USSL3 Serenissima, Mestre, Italy.

Luigi Chiumarulo (L)

Policlinico, Bari, Italy.

Marco Petruzzellis (M)

Policlinico, Bari, Italy.

Marco Doddi (M)

Presidio Ospedaliero SS. Filippo e Nicola, Avezzano, Italy.

Antonio Carolei (A)

Presidio Ospedaliero SS. Filippo e Nicola, Avezzano, Italy.

William Auteri (W)

Azienda Ospedaliera Annunziata, Cosenza, Italy.

Alfredo Petrone (A)

Azienda Ospedaliera Annunziata, Cosenza, Italy.

Riccardo Padolecchia (R)

Santa Corona Hospital, Pietra Ligure, Italy.

Tiziana Tassinari (T)

Santa Corona Hospital, Pietra Ligure, Italy.

Marco Pavia (M)

Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy.

Paolo Invernizzi (P)

Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy.

Gianni Turcato (G)

Girolamo Fracastoro Hospital, San Bonifacio (Verona), Italy.

Stefano Forlivesi (S)

Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Elisa Francesca Maria Ciceri (E)

Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Bruno Bonetti (B)

Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Domenico Inzitari (D)

University of Florence, Firenze, Italy.

Danilo Toni (D)

Sapienza University Hospital, Roma, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH